PBLD

Across TCGA pan-cancer cohorts, PBLD Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PBLD data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PBLD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PBLD expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

ACC, COAD, and CESC are the cancer types where PBLD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
COAD	OS	Median	All	0.580	0.872	<.001	27	view →
CESC	DFS	Median	All	0.170	0.556	.010	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.948	0.617	.046	4	view →
LUSC	DFS	Median	All	1.000	0.386	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PBLD–ACC (DFS)

Open the ACC breakdown →